KIN-213 / N8 Medical - LARVOL DELTA

Kinnear Pharmaceuticals Files Pre-IND Meeting Request Letter with U.S. FDA for new CF drug (EIN News) - "Kinnear Pharmaceuticals...is pleased to announce that it filed a pre- Investigational New Drug ('IND') meeting request letter with the U.S. Food and Drug Administration ('FDA') to discuss the drug development plan for its inhaled drug to treat cystic fibrosis patients."

FDA event • Cystic Fibrosis